A carregar...
Clinical Outcomes in Recurrent Glioblastoma with Bevacizumab therapy: An Analysis of the Literature
Bevacizumab (BEV) is a common treatment for recurrent glioblastoma (GBM). After progression on BEV, there is no consensus on subsequent therapy, as multiple chemotherapy trials have failed to demonstrate discernible activity for salvage. A previous review (995 patients) estimated a progression free...
Na minha lista:
Publicado no: | J Clin Neurosci |
---|---|
Main Authors: | , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5581989/ https://ncbi.nlm.nih.gov/pubmed/28711289 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jocn.2017.06.070 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|